Results 61 to 70 of about 131,034 (316)
Evaluation of peripheral serotonergic activation for the treatment of NAFLD
reservedLa steatosi epatica non alcolica o NAFLD, caratterizzata da un eccessivo accumulo di lipidi nel fegato, è considerata una condizione benigna reversibile; ha una prevalenza del 20-30% nei paesi occidentali, 30-50% nei pazienti con diabete mellito
CADORE, ALESSANDRO
core
Non-alcoholic fatty liver disease (NAFLD), the leading cause of chronic liver disease in Western countries, has been identified as a possible risk factor for COVID-19 severity.
Vince, Adriana +7 more
core +1 more source
Practice Guidelines on NAFLD [PDF]
To The Editor: I read with interest the practice guidelines on nonalcoholic fatty liver disease (NAFLD),1 in which the authors fail to reference the association between high fructose corn syrup (HFCS) and NAFLD. The intake of HFCS, a combination of glucose and fructose, has increased over time and parallels both the obesity and NAFLD epidemics.2 ...
openaire +2 more sources
Abstract Nonalcoholic fatty liver disease (NAFLD) is increasing in prevalence and severity globally, prompting noninvasive testing, yet limited data exist on noninvasive liver tests (NITs) including transient elastography (TE) in ethnically diverse populations.
Anne‐Marieke van Dijk +6 more
wiley +1 more source
THE PREVALENCE OF NON-ALCOHOLIC FATTY LIVER DISEASE IN OUTPATIENTS IN THE FAR EAST FEDERAL DISTRICT
The rapidly growing incidence of obesity and diabetes mellitus, especially in developed countries, stimulates medical experts to closely study the epidemiology of non-alcoholic fatty liver disease (NAFLD).
V. A. Nevzorova +5 more
doaj +1 more source
This study reveals that NF‐κB1‐driven TRAIP upregulation in ALD correlates with disease severity. Mechanistically, TRAIP directly binds β‐catenin via its CC domain and promotes its K48‐linked ubiquitination and degradation, which is independent of the GSK3β/β‐TrCP pathway.
Zhan Wu +13 more
wiley +1 more source
Oup (n = 10) at SNP rs2290602 (p = 0.0454).Copyright information:Taken from "Association between PPARGC1A polymorphisms and the occurrence of nonalcoholic fatty liver disease (NAFLD)"http://www.biomedcentral.com/1471-230X/8/27BMC Gastroenterology 2008;8()
Hironori Mawatari (94243) +20 more
core +1 more source
The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD) consists of the entire spectrum of fatty liver disease in patients without significant alcohol consumption, ranging from nonalcoholic fatty liver (NAFL) to nonalcoholic steatohepatitis (NASH) to cirrhosis, with ...
Norifumi Kawada +2 more
core +1 more source
OAF Blocks SIAH1‐Mediated Degradation of SCPX, a Therapeutic Strategy for MASLD
This study shows OAF directly binds to SCPX and inhibits its interaction with the E3 ligase SIAH1, thereby protecting SCPX from ubiquitin‐dependent degradation and stabilizing its levels. This OAF‐SCPX axis represents a novel pathway in lipid homeostasis, highlighting OAF as a promising therapeutic candidate for MASLD.
Zongxi Li +11 more
wiley +1 more source
Glucokinase links Kruppel-like factor 6 to the regulation of hepatic insulin sensitivity in nonalcoholic fatty liver disease [PDF]
The polymorphism, KLF6-IVS1-27A, in the Krüppel-like factor 6 (KLF6) transcription factor gene enhances its splicing into antagonistic isoforms and is associated with delayed histological progression of nonalcoholic fatty liver disease (NAFLD).
Gastaldelli, Amalia +103 more
core +1 more source

